Thu, February 27, 2020

Charles Duncan Reiterated (ACAD) at Buy with Increased Target to $75 on, Feb 27th, 2020

Charles Duncan of Cantor Fitzgerald, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $70 to $75 on, Feb 27th, 2020.

Charles has made no other calls on ACAD in the last 4 months.



There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Charles's Rating of Hold.



This is the rating of the analyst that currently disagrees with Charles


  • Yatin Suneja of "Guggenheim" Initiated at Strong Buy and Held Target at $60 on, Monday, December 16th, 2019